Clinical Trial Update: Pegzilarginase in Subjects <24 Months Old With Arginase 1 Deficiency [Phase 3]

View source ↗

Summary

This update notes the completion of a Phase 3 clinical trial evaluating pegzilarginase for Arginase 1 Deficiency in children under 24 months.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arginase Deficiency

Drugs mentioned

• Pegzilarginase (pegzilarginase)

Snippet

Sponsor: Immedica Pharma AB | Conditions: Arginase 1 Deficiency | Phase 3 | Status: COMPLETED